Phaseline

Targets › BAG3

BAG3 (BAG family molecular chaperone regulator 3): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 1; Cardiovascular; next expected readout Dec 2028.

Co-chaperone and adapter protein that connects different classes of molecular chaperones including heat shock proteins 70 (HSP70s), e.g. HSPA1A/HSP70 or HSPA8/HSC70, and small heat shock proteins (sHSPs), e.g. (UniProt, O95817)

Open in Phaseline: the race on BAG3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Affinia TherapeuticsAFTX-201
AAV gene therapy delivering BAG3 transgene
BAG3Phase 1Dilated Cardiomyopathy (DCM)Dec 2028
Rocket PharmaceuticalsRP-A701
AAV gene therapy delivering BAG3 transgene via AAVrh.74 capsid
BAG3Phase 1Dilated Cardiomyopathy (DCM)Jun 2029
AstraZenecaALXN2350
AAV9-mediated BAG3 gene therapy
BAG3Phase 1BAG3 Mutation Associated Dilated CardiomyopathyJan 2032

Conditions

Dilated Cardiomyopathy (DCM) (2) BAG3 Mutation Associated Dilated Cardiomyopathy (1)

Modalities

other (2), small molecule (1)

Companies

AstraZeneca (1) Rocket Pharmaceuticals (1) Affinia Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.